R. Douglas Norby is Director at ALEXION PHARMACEUTICALS INC (ALXN). They have made 11 open-market trades across 3 companies since 2006, most recently 2018-05-09.
CIK 0001227001
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $94K since 2018, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KRYS | BUY | 2018-05-09 | 2018-05-11 | $10.42 | $94K | -0.4% | +42.8% | +55.6% |
| ALXN | SELL | 2015-12-11 | 2015-12-15 | $187.71 | $8.5M | -15.6% | -10.5% | -28.1% |
| ALXN | SELL | 2013-05-22 | 2013-05-23 | $102.77 | $4.1M | -15.6% | -1.2% | -1.2% |
| ALXN | SELL | 2012-12-10 | 2012-12-12 | $93.00 | $2.0M | -15.6% | -1.2% | -1.2% |
| ALXN | SELL | 2012-03-08 | 2012-03-12 | $85.01 | $2.6M | -15.6% | -1.2% | -1.2% |
| ALXN | SELL | 2011-10-27 | 2011-10-31 | $68.00 | $3.1M | -15.6% | -1.2% | -1.2% |
| ALXN | SELL | 2011-02-14 | 2011-02-16 | $89.93 | $2.1M | -15.6% | -1.2% | -1.2% |
| ALXN | SELL · 10b5-1 | 2009-11-03 | 2009-11-04 | $43.94 | $659K | -15.6% | -1.2% | -1.2% |
| ALXN | SELL · 10b5-1 | 2009-08-24 | 2009-08-25 | $45.00 | $765K | -15.6% | -1.2% | -1.2% |
| ALXN | SELL · 10b5-1 | 2009-08-04 | 2009-08-06 | $45.00 | $90K | -15.6% | -1.2% | -1.2% |
| ALXN | SELL · 10b5-1 | 2009-06-19 | 2009-06-19 | $40.28 | $806K | -15.6% | -1.2% | -1.2% |
| ALXN | SELL · 10b5-1 | 2009-03-16 | 2009-03-18 | $35.07 | $1.1M | -15.6% | -1.2% | -1.2% |
| ALXN | SELL | 2008-02-20 | 2008-02-20 | $61.58 | $123K | -15.6% | -1.2% | -1.2% |
| TSRA | SELL | 2006-02-23 | 2006-02-27 | $32.30 | $1.6M | -8.8% | -0.3% | -0.3% |
| TSRA | SELL | 2006-01-11 | 2006-01-13 | $30.09 | $840K | -8.8% | -0.3% | -0.3% |
| TSRA | SELL | 2006-01-10 | 2006-01-11 | $28.46 | $130K | -8.8% | -0.3% | -0.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.